Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 6 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 1 February 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023.
Since the announcement 27 February, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 1,682,702 | 1,634,160,237 | |
| 27 February 2023 | 90,000 | 1,009.11 | 90,820,208 |
| 28 February 2023 | 89,790 | 1,001.36 | 89,911,789 |
| 1 March 2023 | 90,263 | 996.13 | 89,913,954 |
| 2 March 2023 | 79,616 | 996.58 | 79,343,501 |
| 3 March 2023 | 90,000 | 1,004.98 | 90,448,110 |
| Accumulated under the programme | 2,122,371 | 2,074,597,798 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 29,268,697 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 28 billion during a 12-month period beginning 1 February 2023. As of 3 March 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 2,122,371 B shares at an average share price of DKK 977.49 per B share equal to a transaction value of DKK 2,074,597,798.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.
Contact for further information
| Media: | |
| Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com | Natalia Salomao Abrahao (US) +1 848 304 1027 niaa@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
Company announcement No 16 / 2023
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Storaktionærmeddelelse25.3.2023 14:30:37 CET | pressemeddelelse
Årets meddelelse nr. 20 Dato: 25. marts 2023 Storaktionærmeddelelse Det skal herved meddeles, at Pharma Equity Group A/S har modtaget meddelelse om at NK Invest ApS ejerandel, både direkte og indirekte via dennes ejerskab af Selskabet af 25. marts DK ApS og Selskabet af 25. marts II ApS, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 % af den udstedte aktiekapital i Pharma Equity Group A/S. Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: peter.ole.jensen@pharmaequitygroup.com. Med venlig hilsen Pharma Equity Group A/S På bestyrelsens vegne
FCB Tops 2023 WARC Rankings for Creative Effectiveness24.3.2023 21:41:59 CET | Press release
FCB awarded #1 Creative Agency & #1 Campaign for Effectiveness in WARC Effective 100 NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- FCB was a top performer in the 2023 WARC Rankings, earning recognition as the #1 Creative Agency for Effectiveness in the WARC Effective 100, among other distinctions. Numerous FCB campaigns were honored as well, including Michelob ULTRA’s “Contract for Change,” which ranked as the #1 Campaign for Effectiveness. “Creative is the business and the business is creative. To separate the two does a disservice to the industry. We will continue to partner with our clients to create work that is both effective in the moment and impactful long term. FCB is honored that this Timely and Timeless approach to work is being recognized by WARC,” said Susan Credle, FCB Global Chair & Global CCO. In the Effective 100, FCB New York was named the #1 Creative Agency for Effectiveness, joined by two additional FCB agencies, with FCB Chicago ranking #4 and FCB Toronto ranking #7,
Ordinary and Extraordinary General Meeting of April 12, 202324.3.2023 21:30:00 CET | Press release
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches pari
TGS: Approval of 2022 Financial Result24.3.2023 20:03:58 CET | Press release
Oslo, Norway (24 March 2023) – The Board of Directors of TGS ASA has today approved the financial statements for 2022. The financial statements were prepared in accordance with IFRS. Please see the attachment for a summary of changes from the preliminary annual accounts announced on 9 February 2023. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS.com (http://www.tgs.com) or contact: Sven Børre Larsen CFO Tel: +47 90 94 36 73 E-mail: investor@tgs.com Attachment TGS Annual Accounts 2022 update
Nokia Corporation: Repurchase of own shares on 24.03.202324.3.2023 20:00:00 CET | Press release
Nokia Corporation Stock Exchange Release 24 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 24.03.2023 Espoo, Finland – On 24 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL306,0764.31CEUX7,3924.31AQEU2,6084.31TQEX6,3244.32Total322,4004.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and